Omalizumab interactions
Full monograph for OmalizumabCheck it against another medicine
Medicines
14 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Beta carotene + Vitamin C + Vitamin E | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Carbonyl Iron + Folic Acid + Zinc Sulfate | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Carbonyl Iron + Folic Acid + Zinc Sulfate + Vitamin B Complex + Vitamin C | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Diphenhydramine Hydrochloride + Zinc Acetate | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Ferrous Ascorbate + Folic Acid + Zinc Sulfate | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Ferrous Sulfate + Folic Acid + Zinc Sulfate | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Glycerin + Hypromellose + Polyethylene glycol + Tetrahydrozoline + Zinc Sulfate | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Iron + Folic Acid + Vitamin B Complex + Vitamine C + Zinc Sulfate | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Iron Polymaltose Complex + Folic Acid + Zinc Sulfate | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Naphazoline + Zinc Sulfate | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Tea tree oil + Echinacea + Geothermal water | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Tea Tree Oil + Geothermal Water + Vitamin E | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Vitamin C + Vitamin E | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Vitamin C + Vitamin E + Lutein + Copper + Zinc | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
Conditions
Conditions in which Omalizumab needs care, as documented in this source.
Neoplasms
ModerateIn clinical trials malignancies have been observed in patients receiving omalizumab. Periodic examination is recommended for all patients, particularly those with risk factors for cancer. Caution should be exercised when considering omalizumab for the treatment of patients with a history of malignancies, those who have a known malignancy, or when continuing treatment in patients who develop malignancy while receiving this agent.
1 source
- "Product Information. Xolair (omalizumab)." Genentech (2003):